NCT06360627 Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT
| NCT ID | NCT06360627 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Radiation Exposure |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-02-20 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-02-20 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT
Eligibility Criteria
Inclusion Criteria: * CT SCAN for pulmonary nodule detection/follow up * CT SCAN for pneumonia detection/follow up Exclusion Criteria: * under 18 * BMI over 30
Frequently Asked Questions
Who can join the NCT06360627 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Radiation Exposure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06360627 currently recruiting?
Yes, NCT06360627 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Zurich to inquire about joining.
Where is the NCT06360627 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT06360627 clinical trial?
NCT06360627 is sponsored by University of Zurich. The trial plans to enroll 100 participants.